CHEK1 and cancer: As an ATP-competitive inhibitor, prexasertib (also known as ACR-368 or LY2606368) potently inhibited CHK1, and CHK2 to a lesser extent.235 Prexasertib treatment induced replication catastrophe, premature mitosis and apoptosis in cancer cells.